𝔖 Bobbio Scriptorium
✦   LIBER   ✦

High dose dexamethasone and base of brain irradiation for hormone refractory metastatic carcinoma of the prostate

✍ Scribed by K. Hellmann; R. H. Phillips; M. Goold

Publisher
Springer
Year
1993
Tongue
English
Weight
242 KB
Volume
11
Category
Article
ISSN
0262-0898

No coin nor oath required. For personal study only.

✦ Synopsis

High dose dexamethasone combined with irradiation to the base of the brain achieved a dramatic beneficial effect in two terminal cases of widespread metastatic carcinoma of the prostate involving cranial nerves and the entire skeleton. Pain requiring very large doses of analgesics and anemia requiring blood transfusions every 3-4 weeks were improved rapidly. No further transfusions were needed.

📜 SIMILAR VOLUMES

High-dose calcitriol, zoledronate, and d
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma
✍ Michael J. Morris; Oren Smaletz; David Solit; W. Kevin Kelly; Susan Slovin; Carl 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

## Abstract ## BACKGROUND Preclinical and clinical data have suggested that high‐dose calcitriol (1,25‐dihydroxycholecalciferol) has activity against prostate carcinoma. Pulse‐dosed calcitriol and dexamethasone may maximize tolerability and efficacy. The authors examined the toxicity of pulse‐dose

Weekly administration of docetaxel for s
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma : Evaluation of clinical benefit, quality of life, and tolerance
✍ Gwenaelle Gravis; Franck Bladou; Naji Salem; Geneviève Macquart-Moulin; Gérard S 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND The current Phase II study investigated the clinical benefit, impact on quality of life (QOL), and tolerability of weekly docetaxel in symptomatic patients with metastatic hormone‐refractory prostate carcinoma (HRPC). ## METHODS Patients received weekly docetaxel 35 mg/

Phase 1/2 dose-escalation study of a GM-
Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
✍ Celestia S. Higano; John M. Corman; David C. Smith; Arthur S. Centeno; Christoph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

## Abstract ## BACKGROUND This open‐label, multicenter, dose‐escalation study evaluated multiple dose levels of immunotherapy in patients with metastatic hormone‐refractory prostate cancer (HRPC). The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate‐carcinoma cell line